Darunavir
- Generic Name
- Darunavir
- Brand Names
- Prezcobix, Prezista, Rezolsta, Darunavir Viatris (previously Darunavir Mylan), Darunavir Krka
- Drug Type
- Small Molecule
- Chemical Formula
- C27H37N3O7S
- CAS Number
- 206361-99-1
- Unique Ingredient Identifier
- YO603Y8113
- Background
Darunavir is a protease inhibitor used with other HIV protease inhibitor drugs as well as ritonavir for the effective management of HIV-1 infection. As a second-generation protease inhibitor, darunavir is designed to combat resistance to standard HIV therapy. It was initially approved by the FDA in 2006.
...
- Indication
Darunavir, co-administered with ritonavir, and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV) in children age 3 or above and adults with HIV-1 infection.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed Conditions
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 22
- Registration Number
- NCT04718805
- Locations
- 🇧🇪
SGS Clinical Pharmacology Unit (located in ZNA Stuivenberg), Antwerpen, Belgium
A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents
- Conditions
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 37
- Registration Number
- NCT04661397
- Locations
- 🇳🇱
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands
A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents
- Conditions
- Interventions
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 16
- Registration Number
- NCT04236453
- Locations
- 🇳🇱
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands
A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 28
- Registration Number
- NCT04208061
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
Inflammation and Co-Infections in D²EFT
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- Kirby Institute
- Registration Number
- NCT04183738
Nucleosides And Darunavir/Dolutegravir In Africa
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- Makerere University
- Target Recruit Count
- 465
- Registration Number
- NCT03988452
- Locations
- 🇺🇬
Infectious Diseases Institute, Kampala, Uganda
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
- Conditions
- Interventions
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2019-03-28
- Lead Sponsor
- Makerere University
- Target Recruit Count
- 60
- Registration Number
- NCT03589040
- Locations
- 🇺🇬
Infectious Diseases Institue, Kampala, Uganda
Optimization of Darunavir Therapy and Dosage Recommendations
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2019-09-03
- Lead Sponsor
- Université Catholique de Louvain
- Target Recruit Count
- 127
- Registration Number
- NCT03101644
- Locations
- 🇧🇪
Cliniques universitaires Saint-Luc, Brussels, Belgium
Dolutegravir and Darunavir Evaluation in Adults Failing Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 831
- Registration Number
- NCT03017872
- Locations
- 🇦🇷
Hospital G de Agudos JM Ramos Mejia, Buenos Aires, Ciudad De Buenos Aires, Argentina
🇦🇷Hospital Dr Diego Paroissien, Isidro Casanova, Provincia De Buenos Aires, Argentina
🇦🇷CAICI, Rosario, Provincia De Santa Fe, Argentina
Evaluation of Low-dose Darunavir in a Switch Study
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Willem Daniel Francois Venter
- Target Recruit Count
- 300
- Registration Number
- NCT02671383
- Locations
- 🇿🇦
Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, Gauteng, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.